Posted by Adam Awdish on
Rabbit tPA Recombinant Active from Innovative Research was used in the following study:
Jonathon B. Young; Amanda Rae Buchberger; Joseph D. Bogaard; Linda Berg Luecke; Matthew Runquist; Christine M. B. Skumatz; Iris S. Kassem
Translational Vision Science & Technology
Despite advances in the ability to treat cataracts over the years, children with cataracts and pediatric patients suffering from Uveitis tend to express increased inflammation and fibrin scarring following intraocular surgery. This exaggerated immune response following operation has the potential to cause the formation of a pupillary membrane or of pupil displacement, potentially leaving the child with vision that is still limited following treatment due to amblyopia. This risk is considered when deciding whether the child will receive an intraocular lens (IOL) during their surgery as adult patients do, or to leave the pediatric patient without a lens (aphakic) and a prescription for contact lenses.
IOL implementation is the preferred treatment as up to 18% of pediatric patients suffer from complications with the insertion, removal, and maintenance of contact lenses. When surgery is needed to treat cataracts resulting from Uveitis patients require even more aggressive anti-inflammatory treatments both before and after surgery to manage the potential for severe complications.
This study aimed to better understand the mechanisms responsible for ocular inflammation and fibrin formation following surgery, as well as investigate possible methods for treatment and prevention of adverse ocular events following intraocular surgery. Their tests identified several proteins that increased in concentration immediately following tPA treatment, which is used to reduce scarring after intraocular surgery.
Related products available from Innovative Research also include: